PolyPid Ltd. (PYPD)
| Market Cap | 89.45M +213.5% |
| Revenue (ttm) | n/a |
| Net Income | -33.63M |
| EPS | -1.78 |
| Shares Out | 19.17M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,096 |
| Open | 4.600 |
| Previous Close | 4.620 |
| Day's Range | 4.586 - 4.700 |
| 52-Week Range | 3.060 - 5.210 |
| Beta | 1.42 |
| Analysts | Strong Buy |
| Price Target | 12.25 (+162.59%) |
| Earnings Date | May 13, 2026 |
About PYPD
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral ca... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for PYPD stock is "Strong Buy." The 12-month stock price target is $12.25, which is an increase of 162.59% from the latest price.
News
PolyPid completes NDA submission to FDA for D-PLEX100
PolyPid (PYPD) announced the completion of its new drug application, or NDA, submission on a rolling review basis to the FDA for D-PLEX100, the company’s lead product candidate for the…
PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀
If approved, D-PLEX100 would address a critical unmet medical need in the prevention of surgical site infections
PolyPid Transcript: Lytham Partners Spring 2026 Investor Conference
D-PLEX100 is advancing through regulatory milestones, with FDA and EU approvals targeted for 2027. Phase III data show significant reductions in infection rates and severity, and strong market interest is supported by cost-saving incentives and NTAP eligibility.
PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference
PETACH TIKVA, Israel, May 20, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elev...
PolyPid reports Q1 EPS (35c), consensus (43c)
“The first quarter of 2026 marked an important transition for PolyPid (PYPD), as we moved from late-stage development to the final stage prior to drug approval, the regulatory review stage,…
PolyPid Earnings Call Transcript: Q1 2026
Transitioned to final NDA submission for D-PLEX100, with U.S. partnership talks in late stages and European MAA submission planned for Q3 2026. Q1 net loss improved year-over-year, cash position strengthened by loan repayment, and clinical data supports product efficacy.
PolyPid Earnings release: Q1 2026
PolyPid released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results
Initiated NDA Submission to the FDA for D-PLEX₁₀₀ ; Completion Expected Imminently U.S. Commercial Partnership Discussions in Late Stages Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKV...
PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026
PETACH TIKVA, Israel, May 06, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elev...
PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting
Analysis demonstrates statistically significant reduction in the severity of surgical wound infections, with potential to lower hospital resource utilization following abdominal colorectal surgery PET...
PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026
Analysis demonstrates D-PLEX₁₀₀ prolonged delivery mechanism ability to deliver continuous release of doxycycline for 30 days at the surgical incision site Analysis demonstrates D-PLEX₁₀₀ prolonged de...
PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA
PolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026 U.S. Commercialization Partnership Negotiations on Track PETACH TIKVA, Israel, March 31, 202...
PolyPid granted $4.3M waiver from FDA for D-Plex application
PolyPid (PYPD) announced that the FDA has granted a small business waiver of the Prescription Drug User Fee Act, or PDUFA, fee of approximately $4.3M for the New Drug Application,…
PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application
FDA Grants $4. 3 Million Small Business Waiver, Enabling Focus on Commercialization Preparations
PolyPid Transcript: The Citizens Life Sciences Conference 2026
D-PLEX₁₀₀ is nearing NDA submission, with robust Phase 3 data showing significant reductions in surgical site infections and related complications. Market entry will focus on colorectal surgery, with plans for broader expansion and a strong emphasis on hospital partnerships and pharmacoeconomic value.
PolyPid Announces Participation in Upcoming Investor Conferences
PETACH TIKVA, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by ele...
PolyPid Earnings Call Transcript: Q4 2025
SHIELD II Phase III trial success and positive FDA feedback position D-PLEX100 for a rolling NDA submission in Q1 2026, with advanced U.S. partnership talks and a strengthened balance sheet. The company is transitioning to commercialization, introducing the Kynatrix platform, and expects cash to last into H2 2026.
PolyPid Annual report: Q4 2025
PolyPid has published its Q4 2025 annual report on February 11, 2026.
PolyPid Earnings release: Q4 2025
PolyPid released its Q4 2025 earnings on February 11, 2026, summarizing the period's financial results.
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
The Company is in Advanced Stage s of Commercial U.S. Partner ship Discussions for D-PLEX₁₀₀
PolyPid Slides: Investor presentation
PolyPid has posted slides in relation to its latest quarterly earnings report, which was published on February 11, 2026.
PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026
PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced th...
PolyPid Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit
A novel drug delivery platform is advancing toward FDA approval, with D-PLEX 100 showing strong phase 3 results in reducing surgical site infections. Commercialization plans include a U.S. partnership, and financial resources are sufficient through 2026.
PolyPid appoints Story as Chairman of Board of Directors
PolyPid (PYPD) announced the appointment of Brooke Story as Chairman of the Board of Directors, effective as of December 11, 2025. Story brings over 25 years of leadership experience in…
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors
Appointment Enhances PolyPid's Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX₁₀₀ New Drug Application Submission Appointment Enhances PolyPid's Strategic, Commercial and Transactio...